Related Experiment Videos
Shared T cell-defined antigens on independently derived tumors
D M Sahasrabudhe1, D Burstyn, J C Dusel
1Cancer Center, University of Rochester School of Medicine and Dentistry, NY 14642.
Journal of Immunology (Baltimore, Md. : 1950)
|December 1, 1993
Summary
Tumors from cloned cells can provide cross-protective immunity in mice. Cytolytic T cells recognize shared tumor rejection antigens, contrasting with diverse tumor profiles.
Area of Science:
- Immunology
- Oncology
- Cancer Research
Background:
- Tumor-specific antigens (TSAs) are crucial for cancer immunotherapy.
- Understanding the antigenic profile of tumors is essential for developing effective cancer vaccines.
- Previous studies indicated significant antigenic diversity in chemically or radiation-induced tumors.
Purpose of the Study:
- To investigate cross-protective immunity among tumors derived from a cloned cell line.
- To characterize the antigenic profile of these independently derived tumors.
- To determine if shared tumor rejection antigens are expressed.
Main Methods:
- Independently derived tumor lines from cloned murine fetal fibroblasts.
- In vivo immunization and challenge experiments.
- Generation and characterization of cytolytic T cell clones.
- In vitro tumor cell lysis assays.
Main Results:
- A subset of independently derived tumors conferred cross-protective immunity in vivo.
- Cytolytic T cell clones specifically lysed tumor lines sharing antigenic profiles.
- No cross-reactivity was observed with the parental non-tumorigenic cell line.
- These findings suggest shared expression of tumor rejection antigens.
Conclusions:
- Tumors derived from a cloned cell line can express shared tumor rejection antigens.
- This shared antigenicity can elicit cross-protective immunity.
- Distinguishing between transformation-associated antigens and mutation-induced antigens is critical for interpreting tumor immunology data.